Our Cell Bank Technology
Automated Processing Technology
ThermoGenesis (Nasdaq:THMO) is a major shareholder of ImmuneCyte. ThermoGenesis is a pioneer in the field of automated cellular processing. Its AutoXpress (AXP) platform is the leading automation technology for all cord blood banks worldwide. More than 1,000,000 automated processing procedures have been performed worldwide.
Multi-Component Automated Separation System (MCASS™) is Proprietary cGMP compliant, automated system for Immune Cell Processing. It allows simultaneous isolation of different cell components from blood within a closed system, allowing for safe and quality assurance for the future. This system is not available for use at any other US based cell banks. Without using the proprietary and automated technology, immune cells can only be extracted using Ficoll manual method; thus, leading to a higher risk of contamination and cell quality.
Automated Processing Technology
ThermoGenesis (Nasdaq:THMO) is a major shareholder of ImmuneCyte. ThermoGenesis is a pioneer in the field of automated cellular processing. Its AutoXpress (AXP) platform is the leading automation technology for all cord blood banks worldwide. More than 1,000,000 automated processing procedures have been performed worldwide.
Multi-Component Automated Separation System (MCASS™) is Proprietary cGMP compliant, automated system for Immune Cell Processing. It allows simultaneous isolation of different cell components from blood within a closed system, allowing for safe and quality assurance for the future. This system is not available for use at any other US based cell banks. Without using the proprietary and automated technology, immune cells can only be extracted using Ficoll manual method; thus, leading to a higher risk of contamination and cell quality.
Cryo-Storage Technology
Processed cells will be stored in the individualized storage space of our automated storage system BioArchive®. BioArchive® is a leading platform that has been used for storing cell therapies known as BLAs (Biological License Applications), such as cord blood samples approved by the FDA.
Significant Advantages
- Close automated system for quality
- Multi-component separation and storage capability
- cGMP compliant
- 200ml of blood collection instead of 50ml blood collection, amount required for a single therapy.
Significant Advantages
- Close automated system for quality
- Multi-component separation and storage capability
- cGMP compliant
- 200ml of blood collection instead of 50ml blood collection, amount required for a single therapy.
Subscribe to Our Newsletter & Special Promotions
Disclaimer: The use of cord blood and immune cells is determined by the treating physician and manufacturer of the final products and is influenced by many factors, including the patient's medical condition, the characteristics of the sample, and whether the immune cells should be further modified or expanded. Cord blood has established uses in transplant medicine; however, its use in regenerative medicine is still being researched. There is no guarantee that potential medical applications being studied in the laboratory or clinical trials will become available. Cord tissue use is still in early research stages, and there is no guarantee that treatments using cord tissue will be available in the future. Cord tissue is stored whole. Additional processing prior to use will be required to extract and prepare any of the multiple cell types from cryopreserved cord tissue. Immune cells has established uses in certain blood cancer treatment; however, its use in solid cancer is still being researched. There is no guarantee that treatments being studied in the laboratory, clinical trials, or other experimental treatments will be available in the future.
HealthBanks cryopreserves immune cells that have been collected from an individual for potential future cellular therapy use. HealthBanks does not provide medical advice, treatment or care. The use of cryopreserved cells for future immunotherapies is not guaranteed. Much is yet unknown about the future of immunotherapy and the immune cells that have been cryopreserved. The use of cryopreserved cells by commercial manufacturers for CAR-T therapy production is not currently approved by the FDA. There is active research ongoing, however, there is no guarantee that your cryopreserved cells will have a future therapeutic use. Only your health care professional can help you evaluate whether your cells might be used and if so, how they might be used. HealthBanks and its shareholders, directors, officers, agents, employees, affiliates, network of providers and provider facilities, will not be liable to you or any other party for claims relating to sample collection or if your cells cannot be used, or if any harm, injury, damage or loss results from the use of your cells. For more information, please refer to HealthBanks Service Agreement.